A Phase 1, First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacokinetics of AMG 820 in Adult Subjects With Advanced Solid Tumors

Trial Profile

A Phase 1, First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacokinetics of AMG 820 in Adult Subjects With Advanced Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs AMG 820 (Primary)
  • Indications Colorectal cancer; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
  • Sponsors Amgen
  • Most Recent Events

    • 27 Jun 2017 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 20 Apr 2016 Results assessing safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of AMG 820 presented at the 107th Annual Meeting of the American Association for Cancer Research
    • 14 Jan 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top